IONS Phase 3 readout: a negative outcome, -23.9%

On July 9, 2026, Donidalorsen — Ionis Pharmaceuticals, Inc. (Hereditary Angioedema) reached its Phase 3 readout. The result was a negative outcome, and the stock moved -23.9% in the window around the event. It had already run +11.5% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.